Novo Nordisk Launches Plosbrio and Poviztra Brands in Canada
Novo Nordisk has received Health Canada approval to market semaglutide under two additional brand namesāPlosbrio and Poviztraāexpanding its product portfolio as generic competition approaches in 2026.
New Brand Names Approved
The Danish pharmaceutical company recently secured regulatory approval from Health Canada to sell its semaglutide medication under the brand names Plosbrio and Poviztra, in addition to its existing Ozempic and Wegovy products. This strategic move comes as the company's regulatory exclusivity for semaglutide expired on January 4, 2026, opening the Canadian market to generic manufacturers.
The approval allows Novo Nordisk to maintain multiple branded versions of semaglutide in the Canadian market, potentially offering different pricing strategies and market positioning as generic alternatives become available.
Timing Amid Generic Competition
Health Canada is currently reviewing nine applications for generic semaglutide versions from various pharmaceutical companies. The introduction of Plosbrio and Poviztra comes at a critical time as generic manufacturers prepare to enter the Canadian market throughout 2026.
Canada represents the only country where Novo Nordisk allowed its semaglutide patent to expire, making it a unique testing ground for generic competition. This has attracted international attention from generic manufacturers seeking to establish reference pricing for global markets.
Regulatory Strategy
The launch of multiple brand names appears to be part of Novo Nordisk's competitive response to the anticipated arrival of generic alternatives. Companies often use brand proliferation strategies to maintain market share when facing generic competition.
Canadian patients and healthcare providers can track the availability and pricing of these new brands alongside existing options using our insurance coverage checker and generic semaglutide tracker.
Market Impact
The introduction of Plosbrio and Poviztra adds to the growing complexity of the Canadian GLP-1 medication market. Healthcare providers and pharmacists will need to navigate multiple brand options while generic alternatives from companies like Vimy Pharma, Aspen Pharmacare, and others prepare for market entry.
Pharmaceutical experts expect the expanded brand portfolio could influence pricing negotiations with provincial drug plans and private insurers as the market becomes more competitive throughout 2026.
Looking Ahead
The approval of these additional brand names positions Novo Nordisk to compete more effectively as generic manufacturers begin launching their semaglutide products. The first generic versions are expected to reach Canadian pharmacies between May and September 2026, depending on Health Canada's review timeline.
Patients interested in understanding their options can visit our FAQ section for more information about brand name versus generic medications and coverage considerations.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
Weāll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 ā be the first to know
